C Schroeder
Pulmonary Disease · Beverly Hills, CANPI 1386755346
Payments from drug & device makers
Across 508 payments — averaging $810.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$332K
- Sanofi US Services Inc.$73K
- Viiv Healthcare Company$2K
- AstraZeneca$1K
- AbbVie$560
- Johnson & Johnson$328
- plus $3K from 35 others
What the payments were for
- Consulting fees$4,2252%
- Speaking & faculty fees$245,25091%
- Travel & lodging$8,7273%
- Food & beverage$10,0234%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$135,732
- NUCALA$15,675
- ANORO$7,447
- ANORO ELLIPTA$1,200
- BREZTRI$239
How this compares
$411,939 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 38 | $43,047 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $26,412 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $22,569 |
| LinzessLinaclotide | 12 | $7,620 |
| TrintellixVortioxetine Hydrobromide | 11 | $6,144 |
| Levothyroxine Sodium | 72 | $3,496 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,384 |
| SynthroidLevothyroxine Sodium | 32 | $1,646 |
| PaxlovidNirmatrelvir/Ritonavir | 28 | $1,429 |
| Rosuvastatin Calcium | 51 | $1,149 |
| Bupropion XlBupropion Hcl | 12 | $1,001 |
| Estradiol | 17 | $893 |
| Liothyronine Sodium | 22 | $767 |
| ValacyclovirValacyclovir Hcl | 22 | $765 |
| Nebivolol Hcl | 20 | $753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $332,254 | $48,98170 claims |
| Lilly USA, LLCMounjaro | $227 | $43,04738 claims |
| AbbVieLinzess, Synthroid | $560 | $9,26544 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $57 | $6,14411 claims |
| AstraZenecaSymbicort | $1,040 | $3,38413 claims |
| PfizerPaxlovid | $47 | $1,42928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Beverly Hills
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.